n Form 10-K filed
with the SEC for the year ended December 31, 2007 and other periodic
reports filed with the SEC. The Company expressly disclaims any intent or
obligation to update these forward-looking statements, except as required
by law.
IDM PHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Three months ended March 31,
2008 2007
Revenues:
Related party revenue $2,401,000 $2,803,000
Research grants and contract revenue - 25,000
License fees, milestones and other revenues 4,000 10,000
Total revenues 2,405,000 2,838,000
Costs and expenses:
Research and development 3,902,000 5,261,000
Selling and marketing 150,000 106,000
General and administrative 2,591,000 2,949,000
Restructuring expense 2,576,000 -
Total costs and expenses 9,219,000 8,316,000
Loss from operations (6,814,000) (5,478,000)
Interest income 238,000 113,000
Interest expense (4,728,000) (246,000)
Foreign exchange loss (852,000) (313,000)
Loss before income tax (12,156,000) (5,924,000)
Income tax benefit (expense) 20,000 (44,000)
Net loss $(12,136,000) $(5,968,000)
Weighted average number of shares
outstanding 25,162,411 15,420,788
Ba
'/>"/>
SOURCE IDM Pharma, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
Vion Pharmaceuticals to Appeal Nasdaq Delisting2.
Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format3.
Patients, Doctors, Pharmacists Praise Bipartisan House Resolution on Compounded Hormones Containing Estriol4.
AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company5.
Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection6.
ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference7.
WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering8.
Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards9.
Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May10.
Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference11.
Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM